Abstract
Waldenstrom’s macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder which despite achieved successes in therapy is characterized by recurrences and refractoriness. Study of molecular biology allowed to use targeted drugs, in particular ibrutinib which acts through suppression of B cell receptor signaling pathway by inhibiting Bruton’s tyrosine kinase. In several large trials, ibrutinib demonstrated its effectiveness and manageable toxicity profile both in patients with newly diagnosed and recurrent/refractory WM. A clinical observation of a patient with WM is presented. Due to minimal response during previous treatment, the patient currently is undergoing monotherapy with ibrutinib with positive antitumor effect, satisfactory tolerability, and absence of significant adverse events. The effect of ibrutinib on humoral immunity during the follow up period was evaluated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
